Obesity

obesity

← back to Endocrinology

Summary

AGA 2022 guideline on pharmacologic management of adults with obesity (BMI ≥30, or ≥27 with weight-related complications) who have inadequate response to lifestyle intervention. Strongly recommends adding long-term pharmacotherapy to lifestyle changes; conditionally suggests semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (moderate certainty), and phentermine and diethylpropion (low certainty). Suggests against orlistat; Gelesis100 hydrogel only in clinical trial setting. Semaglutide prioritized for most patients based on magnitude of net benefit.

Current guideline: AGA 2022 Pharmacologic Management of Obesity · download Anki sub-deck

Versions

• 2022 · AGA — AGA 2022 Pharmacologic Management of Obesity
  • Read the guideline: html · Anki deck
• 2016 · AACE/ACE — AACE/ACE 2016 Obesity Guideline
  • Read the guideline: html

---

Table of contents

• 2022 · AGA